EUVIMEDEUVIMED entdecken
Open Access

Designing a novel therapeutic candidate vaccine for HPV16 using immunoinformatics approach: Targeting E6 and E7 epitopes with TLR4 agonist integration

Zahra Samadi Moghaddam iD, Maryam Mashhadi Abolghasem Shirazi, Rosa Jahangiri, Babak Negahdari, Nasser Hashemi Goradel iD

BioImpacts · 16.05.2026 · 16 · 30943

DOI: 10.34172/bi.30943 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioImpacts, online erschienen am 16.05.2026. Verfasst von Zahra Samadi Moghaddam und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology, Maragheh University of Medical Sciences, Maragheh, Iran. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Although prophylactic vaccinations for human papillomaviruses (HPVs) have been approved, these vaccines lack therapeutic efficacy and cannot eradicate pre-existing infections. Although epitope-based vaccines represent a promising therapeutic vaccine platform, their anti-tumor efficacy has been limited due to low immunogenicity. This study aimed to apply bioinformatics tools to design a built-in adjuvant therapeutic candidate vaccine targeting HPV16 infections and associated cancers.

Methods

The designed vaccine consists of HPV16 E6 and E7 epitopes conjugated to the domain 4 of pneumolysin (Ply4) from Streptococcus pneumonia, which serves as a potential toll-like receptor 4 (TLR4) agonist. In silico analyses were performed to evaluate the vaccine's physicochemical properties, antigenicity, immunogenicity, and binding interactions with the TLR4 receptor. The designed vaccine was expressed in E. coli and its expression was confirmed by SDS-PAGE and Western blot analysis.

Results

In silico analysis predicted that the designed vaccine could have desirable qualities, including non-toxicity, non-allergenicity, antigenicity, immunogenicity, hydrophilicity, and stability. Docking analysis between the vaccine and the TLR4 proteins predicted a high binding capacity and efficient binding. Furthermore, immunoinformatics tools showed that the vaccine could induce robust immune responses, specifically helper and cytotoxic T-cell responses, and promote the production of IFN-γ. The vaccine was successfully expressed in the E. coli system after being cloned into the pET28a vector. SDS-PAGE and Western blotting assays confirmed the purification of the target protein.

Conclusion

The novel built-in adjuvant therapeutic candidate vaccine is a rationally designed construct for eradicating pre-existing HPV infections and HPV-induced cervical cancers that warrants further preclinical evaluation.

Schlagwörter

Stichwörter der Autor:innen

AdjuvantBioinformaticsEpitopeHuman papillomavirusPneumolysinToll-like receptor 4

Autor:innen und Institutionen

  • Department of Medical Biotechnology, Maragheh University of Medical Sciences, Maragheh, Iran.
  • Department of Molecular Virology, Pasteur Institute of Iran, Tehran, Iran.
  • Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Cancer Gene Therapy Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.

ORCID-Profile: Zahra Samadi Moghaddam, Nasser Hashemi Goradel

Zitieren

APA

Samadi Moghaddam, Z., Mashhadi Abolghasem Shirazi, M., Jahangiri, R., Negahdari, B., & Hashemi Goradel, N. (2026). Designing a novel therapeutic candidate vaccine for HPV16 using immunoinformatics approach: Targeting E6 and E7 epitopes with TLR4 agonist integration. BioImpacts, 16, 30943. https://doi.org/10.34172/bi.30943

Vancouver

Samadi Moghaddam Z, Mashhadi Abolghasem Shirazi M, Jahangiri R, Negahdari B, Hashemi Goradel N. Designing a novel therapeutic candidate vaccine for HPV16 using immunoinformatics approach: Targeting E6 and E7 epitopes with TLR4 agonist integration. BioImpacts. 2026;16:30943. doi:10.34172/bi.30943

BibTeX
@article{SamadiMoghaddam2026,
  author = {Samadi Moghaddam, Zahra and Mashhadi Abolghasem Shirazi, Maryam and Jahangiri, Rosa and Negahdari, Babak and Hashemi Goradel, Nasser},
  title = {Designing a novel therapeutic candidate vaccine for HPV16 using immunoinformatics approach: Targeting E6 and E7 epitopes with TLR4 agonist integration},
  journal = {BioImpacts},
  year = {2026},
  volume = {16},
  pages = {30943},
  doi = {10.34172/bi.30943}
}
Kostenlos starten →